RT Journal Article
T1 Immune checkpoint inhibitors-associated thrombosis in patients with lung cancer and melanoma: a study of the Spanish society of medical oncology (SEOM) thrombosis and cancer group.
A1 Cánovas, Manuel Sánchez
A1 Garay, David Fernández
A1 Moran, Laura Ortega
A1 Pérez, Jaime Rubio
A1 Rubio, Carlos Miguel Guirao
A1 de Mena, Miriam Lobo
A1 Portero, Berta Obispo
A1 Castro, Jesús Brenes
A1 Lage, Yolanda
A1 Lavin, Diego Cacho
A1 Blanco, Ana Belen Rupérez
A1 de Soignie, Ana Manuela Martín Fernández
A1 Perejón, Jonatan Zacarías Benoit
A1 Colomo, Laura Jiménez
A1 Boluda, Noel Blaya
A1 Moreno, Javier Bosque
A1 Verduguez, Teresa Quintanar
A1 Garrido, Carmen Rosa
A1 Huertas, Roberto Martín
A1 Puig, Carme Font I
A1 Martín, Andrés Jesús Muñoz
K1 Cancer related thrombosis
K1 Immune Checkpoint Inhibitors
K1 Lung cancer
K1 Melanoma
AB Immune Checkpoint Inhibitors (ICI) can be associated with thrombotic events, both venous and arterial (VTE/AT). However, there is a paucity of information regarding patients in routine clinical practice. Retrospective, multicenter study promoted by the Thrombosis and Cancer Section of the Spanish Society of Medical Oncology (SEOM). Patients with melanoma and lung cancer who initiated ICI between 01/01/2015 and 31/12/2019 were recruited. Minimum follow-up was 6 months (unless it was not possible because of death). The primary objective was to calculate the incidence of ICI-associated VTE/AT and the secondary objectives included to analyze its impact on survival and to identify predictor variables for VTE/AT. 665 patients with lung cancer were enrolled. The incidence of VTE/AT during follow-up was 8.4%. Median overall survival (OS) was lower in the VTE/AT group (12 months 95% CI 4.84-19.16 vs. 19 months 95% CI 16.11-21.9; p = 0.0049). Neutrophil/lymphocyte ratio (NLR) and anemia upon initiation of IT, as well as a history of thrombosis between cancer diagnosis and the start of ICI, were predictive variables for developing of VTE/AT (p  ICI increases the risk of VTE/AT in patients with lung cancer and melanoma, which impact OS.
YR 2022
FD 2022-06-06
LK http://hdl.handle.net/10668/21175
UL http://hdl.handle.net/10668/21175
LA en
DS RISalud
RD Apr 9, 2025